Avalyn Pharma (AVLN)
Develops inhaled pirfenidone and nintedanib candidates for pulmonary fibrosis.
$29.67
After hours−0.12 (−0.40%)
At close$29.79(−8.20%)
Something off on this page? Send us feedback.
EPSReportedEstimate
——————Jun '26Aug '26
Reported——————−$21.83−$0.98
Estimate——————−$5.98−$0.78
Surprise——————−265.3%−26.2%
RevenueReportedEstimate
——————Jun '26Aug '26
Reported————————
Estimate————————
Surprise————————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2026 | −$0.83 | — | — |
| Sep 2026 | −$0.71 | — | — |
| Aug 2026 | −$0.78 | −$0.98 | −26.2% |
| Jun 2026 | −$5.98 | −$21.83 | −265.3% |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2026 | −$0.83 | — | — | $0 | — | — | — |
| Sep 2026 | −$0.71 | — | — | $0 | — | — | — |
| Aug 12, 2026 | −$0.78 | −$0.98 | −26.2% | — | — | — | +5.4% |
| Jun 3, 2026 | −$5.98 | −$21.83 | −265.3% | — | — | — | +2.6% |